A new study presented at ASCO highlights major shortcomings in online resources about artificial intelligence and cancer, emphasizing low quality and lack of comprehensive risk information.
A recent study presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting has revealed significant gaps in the availability and quality of online information regarding artificial intelligence (AI) and its impact on cancer research and treatment. The research, led by experts from the Abramson Cancer Center (ACC) of the University of Pennsylvania and Penn's Perelman School of Medicine, found that while some resources exist, they are often of low quality, difficult to read, and frequently fail to address potential risks associated with AI use.
The study evaluated a range of webpages and videos aimed at both patients and the general public. It was discovered that these materials often lacked essential information necessary for informed decision-making. Specifically, many sources failed to adequately explain the limitations and potential downsides of AI in cancer care, which is crucial for patients and their families who may be considering or undergoing AI-assisted treatments.
Dr. Emily Chen, a lead researcher from the ACC, emphasized the importance of comprehensive and accessible information. "Patients need reliable and understandable resources that not only highlight the benefits but also discuss the potential risks," she stated. "Our findings suggest that there is an urgent need for more high-quality, patient-friendly content."
The researchers recommend that healthcare providers and organizations collaborate to develop clearer and more transparent online materials. They advocate for a focus on user-friendly design and clear communication of both advantages and disadvantages associated with AI in cancer care.
These insights underscore the critical role of accurate and balanced information in supporting informed patient decisions and enhancing public understanding of AI's role in modern oncology practices.
